Patients with NPM1-mutated AML have a more favorable prognosis; those with FLT3-ITD mutations have a poor prognosis, especially among patients with high FLT3 ARs and in the absence of NPM1 mutation. The gene discussed is NPM1; the disease is acute myeloid leukemia.